Summary & Overview
CPT 80181: Flecainide Quantitative Serum Assay
CPT code 80181 represents the technical laboratory test to measure flecainide levels in patient specimens, typically serum. Monitoring flecainide concentrations is clinically important because flecainide is a Class I antiarrhythmic agent with a narrow therapeutic window and potential for serious toxicity at supratherapeutic levels. Nationally, coverage and utilization of therapeutic drug monitoring codes like 80181 affect care pathways for patients with life‑threatening ventricular dysrhythmias who require dose adjustments or toxicity evaluation.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for flecainide testing, typical sites of service for the technical assay, common billing modifiers associated with laboratory technical components, and what to expect in payer coverage patterns. The publication also outlines benchmark topics and policy considerations relevant to laboratory testing for antiarrhythmic drug monitoring.
This summary provides clinicians, laboratory managers, and billing professionals with concise context on why 80181 is used, where the service is performed, and which major payers are relevant for nationwide billing considerations. Data not available in the input is noted where applicable for more detailed benchmarking or policy specifics.
Billing Code Overview
CPT code 80181 describes a clinical laboratory test in which a lab analyst performs the technical component to quantify the concentration of flecainide in a patient specimen, such as serum. Flecainide is a Class I antiarrhythmic medication used to treat life–threatening ventricular dysrhythmias.
Service type: Therapeutic drug monitoring / quantitative drug assay (technical component)
Typical site of service: Clinical laboratory or hospital laboratory where serum or other patient specimens are processed and analyzed.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a history of life‑threatening ventricular arrhythmias who is receiving flecainide for rhythm control. The patient presents to an outpatient or inpatient clinical laboratory for therapeutic drug monitoring when there is concern for toxicity, treatment failure, a medication change, potential drug–drug interaction, renal or hepatic dysfunction, or dose adjustment after a change in clinical status. A blood specimen (serum or plasma) is collected by a phlebotomist or nursing staff and sent to the hospital or reference laboratory. The laboratory analyst performs the technical assay to quantify flecainide concentration (80181). Results are reviewed by the clinical laboratory director and released to the ordering cardiologist, electrophysiologist, or inpatient team for interpretation in the context of symptoms, ECG findings, and concomitant medications. Typical sites of service include hospital outpatient laboratory, inpatient hospital laboratory, and independent clinical reference laboratories; the test may be ordered from cardiology clinics, emergency departments, or inpatient services.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When billing only for the professional (interpretive) component if separate from the technical lab work |